NEW YORK, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

National Beverage Corp.  (NASDAQ: FIZZ) Class Period: July 17, 2014 - July 3, 2018 Lead Plaintiff Deadline: September 17, 2018 Join the action: http://www.zlk.com/pslra-d/fizz-lawsuit?wire=3

Allegations: National Beverage Corp. made materially false and/or misleading statements and/or failed to disclose that: (1) National Beverage's sales claims and its supposed "proprietary techniques" lacked a verifiable basis; (2) the Company's Chairman and CEO engaged in a pattern of sexual misconduct between 2014 and 2016; and (3) as a result, National Beverage's public statements were materially false and misleading at all relevant times.    

On May 4, 2017, National Beverage issued a press release stating that it “employs methods that no other company does in this area—VPO (velocity per outlet) and VPC (velocity per capita).”  National Beverage asserted that it “utilize[s] two proprietary techniques to magnify these measures and this creates growth never before thought possible.” Then on June 26, 2018 the Wall Street Journal reported that National Beverage had declined to provide the U.S. Securities and Exchange Commission with requested sales figures to clarify their sales claims. Then on July 3, 2018, the Wall Street Journal published an article reporting that two pilots had filed lawsuits alleging that National Beverage's CEO had sexually harassed them.  

To learn more about the FIZZ class action contact jlevi@levikorsinsky.com .

Rockwell Medical, Inc. (NASDAQ: RMTI) Class Period: March 16, 2018 - June 26, 2018 Lead Plaintiff Deadline: September 25, 2018 Join the action: http://www.zlk.com/pslra-d/rockwell-medical-inc?wire=3

Allegations: Rockwell Medical, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) Rockwell was aware that The Centers for Medicare and Medicaid Services will not pursue Rockwell’s proposal for separate reimbursement for the drug Triferic; (2) the estimated reserves in the first quarter 2018 10-Q are misstated; (3) there was a material weakness in Rockwell’s internal controls over financial reporting; (4) consequently, Rockwell’s internal controls over financial reporting were ineffective during the Class Period; (5) Defendant Chioini withheld material information regarding Triferic from Rockwell’s auditor, corporate counsel and five independent directors of the Board; and (6) as a result, Defendants’ statements about the Company’s business, operations and prospects were materially false and misleading and/or lacked reasonable bases at all relevant times.

To learn more about the RMTI class action contact jlevi@levikorsinsky.com .

You have until the lead plaintiff deadlines to request the court appoint as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 55 Broadway, 10th Floor New York, NY 10006 jlevi@levikorsinsky.com Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com